Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Retained Earnings (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Retained Earnings for 4 consecutive years, with -$1.2 billion as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 19.98% to -$1.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.2 billion through Dec 2025, down 19.98% year-over-year, with the annual reading at -$1.2 billion for FY2025, 19.98% down from the prior year.
  • Retained Earnings for Q4 2025 was -$1.2 billion at Centessa Pharmaceuticals, down from $2.6 million in the prior quarter.
  • The five-year high for Retained Earnings was $2.6 million in Q3 2025, with the low at -$1.2 billion in Q4 2025.
  • Average Retained Earnings over 4 years is -$437.7 million, with a median of -$339.6 million recorded in 2022.
  • The sharpest move saw Retained Earnings tumbled 131951.92% in 2024, then soared 100.3% in 2025.
  • Over 4 years, Retained Earnings stood at -$1.5 million in 2022, then crashed by 50196.93% to -$752.9 million in 2023, then tumbled by 31.31% to -$988.7 million in 2024, then decreased by 19.98% to -$1.2 billion in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$1.2 billion, $2.6 million, and $1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.